Last updated: September 28, 2026
Cardura is the original branded formulation of doxazosin, an alpha-1 adrenergic blocker approved for hypertension and benign prostatic hyperplasia (BPH). Its commercial trajectory has four phases: rapid adoption in the 1990s, clinical deterioration after the ALLHAT trial, generic erosion after U.S. patent expiry around 2000, and long-term commoditization. Cardura no longer has meaningful U.S. exclusivity, and current value is concentrated in low-cost generic doxazosin rather than the Pfizer brand.
The principal commercial facts are:
- Active ingredient: doxazosin mesylate.
- Main indications: hypertension and symptomatic BPH.
- Original sponsor: Pfizer.
- U.S. approval: Cardura tablets in 1990; Cardura XL extended-release tablets in 2005.
- Core U.S. patent protection: expired around 2000.
- Current U.S. market: generic-dominated, with multiple manufacturers.
- Main demand constraint: clinical preference for other antihypertensives after ALLHAT.
- Current financial exposure: limited for Pfizer and not separately reported as a material product franchise.
What is Cardura and how does doxazosin work?
Cardura contains doxazosin mesylate, a selective alpha-1 adrenergic receptor antagonist. It relaxes vascular smooth muscle and reduces peripheral vascular resistance. In the prostate and bladder neck, it reduces smooth-muscle tone and improves urinary flow.
| Attribute |
Cardura |
| Active ingredient |
Doxazosin mesylate |
| Drug class |
Alpha-1 adrenergic blocker |
| Primary indications |
Hypertension and BPH |
| Initial U.S. approval |
1990 |
| Oral dosage forms |
Immediate-release tablets; extended-release tablets under Cardura XL |
| Original developer |
Pfizer |
| Current U.S. status |
Generic competition; no meaningful brand exclusivity |
| Key competitors |
Terazosin, tamsulosin, alfuzosin, silodosin, finasteride, antihypertensive classes |
| Primary commercial setting |
Generic outpatient prescription market |
Doxazosin is generally administered once daily in immediate-release form, with dose titration required because of orthostatic hypotension and first-dose effects. Cardura XL was designed for controlled release and BPH treatment but did not create a durable commercial moat after the immediate-release product lost exclusivity.
When did Cardura lose patent and regulatory exclusivity?
Cardura’s core U.S. exclusivity ended around 2000, allowing generic doxazosin tablets to enter the market. The original composition and product protection was filed in the 1980s, placing expiry near the end of the standard pre-1995 U.S. patent term framework.
| Milestone |
Approximate timing |
Commercial effect |
| U.S. Cardura approval |
1990 |
Pfizer launched branded doxazosin |
| BPH use expanded |
1990s |
Broader prescribing and revenue growth |
| Core patent expiry |
Around 2000 |
ANDA-based generic entry became possible |
| ALLHAT doxazosin arm terminated |
January 2000 |
Hypertension demand weakened |
| Generic price competition |
2000 onward |
Rapid erosion of brand share and price |
| Cardura XL approval |
2005 |
Limited lifecycle extension |
| Present market |
2020s |
Mature, low-margin generic category |
The exact patent portfolio must be distinguished from regulatory exclusivity. The expiration of the main product patent did not prevent later formulation or method-of-use filings, but those filings did not preserve the original Cardura franchise against broad generic substitution.
What is the Orange Book status of Cardura?
The original Cardura tablet product has no commercially meaningful active U.S. patent barrier. Generic doxazosin approvals have been available for years, and the immediate-release product is treated as an established generic medicine rather than a protected branded product.
Cardura XL had a separate extended-release formulation and a later approval date. Its commercial position was weaker than that of the original tablet because generic immediate-release doxazosin was already established and physicians had inexpensive alternatives. Any historical formulation patents associated with Cardura XL no longer provide a material barrier to ordinary doxazosin treatment.
FDA’s Orange Book and Drugs@FDA records remain the authoritative sources for current listed patents, exclusivity codes, and approved product status. The practical market conclusion is unchanged: Cardura does not have a live, high-value U.S. patent moat. (U.S. Food and Drug Administration [FDA], n.d.-a, n.d.-b)
How did the ALLHAT trial change Cardura demand?
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial materially damaged doxazosin’s position in hypertension. The doxazosin arm was stopped early because patients had a higher risk of heart failure and worse blood-pressure control than patients receiving chlorthalidone.
The National Heart, Lung, and Blood Institute reported that the doxazosin arm had:
- Approximately twice the risk of heart failure.
- A higher combined rate of cardiovascular events.
- Less effective systolic blood-pressure control than chlorthalidone.
- No compensating cardiovascular benefit sufficient to justify continued use as the initial therapy for hypertension.
The findings were published in JAMA in 2000. They shifted clinical use away from alpha-1 blockers as first-line hypertension treatment and toward thiazide diuretics, ACE inhibitors, angiotensin receptor blockers, calcium-channel blockers, and beta blockers in selected patients. (ALLHAT Collaborative Research Group, 2000)
This event coincided with generic entry, creating a compound commercial shock. Cardura lost both price protection and a major prescribing rationale.
What was Cardura’s financial trajectory?
Cardura was a substantial Pfizer product in the 1990s, but its revenue declined sharply after patent expiry and the ALLHAT findings. Pfizer’s annual reports identified Cardura among its established products, with sales reaching roughly the billion-dollar range around the late 1990s before falling after generic competition. The company did not continue reporting Cardura as a major standalone growth asset once generic erosion became established. (Pfizer Inc., 1999, 2000, 2001)
Cardura revenue trajectory
| Period |
Financial position |
Main driver |
| Early to mid-1990s |
Growth product |
Expansion in hypertension and BPH |
| Late 1990s |
Peak commercial period |
Brand prescribing and limited competition |
| 2000-2002 |
Rapid decline |
Patent expiry, generic substitution, ALLHAT |
| Mid-2000s |
Residual brand revenue |
Cardura XL and remaining brand prescriptions |
| 2010s |
Mature generic market |
Low prices and multiple suppliers |
| 2020s |
Minimal brand relevance |
Generic doxazosin dominates dispensing |
The financial trajectory resembles other first-generation cardiovascular brands that lost exclusivity before modern specialty-drug pricing became common. Revenue erosion came from both volume substitution and price compression. Once pharmacies could dispense generic doxazosin under substitution rules, Pfizer’s ability to retain unit economics was limited.
No reliable current standalone Cardura revenue figure is publicly disclosed. Pfizer’s contemporary financial reporting aggregates or omits products that no longer have material revenue. Current market value is therefore better assessed through prescription volume, generic reimbursement, and manufacturer participation than through brand sales.
How does Cardura compare with competing drugs?
Cardura’s competitive position depends on the indication.
Hypertension
Doxazosin is generally not a preferred initial monotherapy for hypertension. Thiazide-type diuretics, ACE inhibitors, ARBs, and calcium-channel blockers have stronger guideline positioning and broader outcome data.
Benign prostatic hyperplasia
Doxazosin remains clinically relevant for BPH, particularly when both urinary symptoms and hypertension are present. Its disadvantages include orthostatic hypotension and blood-pressure effects. Tamsulosin and other uroselective agents are often preferred when minimizing systemic blood-pressure reduction is important.
| Drug |
Class |
Main commercial strength |
Main limitation versus doxazosin |
| Doxazosin |
Alpha-1 blocker |
Low-cost, dual BPH and blood-pressure utility |
Orthostatic hypotension |
| Tamsulosin |
Uroselective alpha-1 blocker |
Strong BPH positioning and less blood-pressure effect |
Limited antihypertensive role |
| Terazosin |
Alpha-1 blocker |
Established generic alternative |
Similar hypotension concerns |
| Alfuzosin |
Uroselective alpha-1 blocker |
BPH use |
Generic competition and cardiovascular cautions |
| Silodosin |
Uroselective alpha-1 blocker |
BPH symptom relief |
Higher cost and ejaculatory adverse effects |
| Finasteride |
5-alpha-reductase inhibitor |
Prostate-size reduction |
Slower onset; sexual adverse effects |
Doxazosin’s low price is its main competitive asset. Its clinical differentiation is limited, and it lacks the patent-protected delivery systems or specialty indications that support premium pricing.
What generic entry risks exist for Cardura?
Generic entry risk is no longer an emerging risk. It is the established market structure.
For immediate-release doxazosin tablets, generic manufacturers can compete through abbreviated new drug applications. The product has a simple oral solid dosage form, established manufacturing processes, and no complex biologic or device component. These factors reduce development cost and regulatory risk.
Generic launch scenarios
| Scenario |
Probability |
Commercial result |
| Additional generic entrants |
High in principle |
Further price pressure, limited volume expansion |
| Brand revival |
Very low |
No evident clinical or patent-based rationale |
| Short-term shortage |
Possible but temporary |
Price or supply volatility without durable brand recovery |
| Premium reformulation |
Low |
Requires meaningful adherence or safety advantage |
| Generic consolidation |
Possible |
Fewer suppliers but continued low pricing |
The main barriers are operational rather than intellectual property-based. They include manufacturing economics, procurement contracts, raw-material supply, quality compliance, and reimbursement rates. These barriers may affect individual suppliers but do not protect Cardura as a brand.
What formulation patents protect Cardura XL?
Cardura XL used an extended-release delivery system intended to control doxazosin release over time. Formulation patents historically could protect release profile, tablet architecture, excipient combinations, or manufacturing processes. That protection was narrower than the active-ingredient protection for immediate-release Cardura.
The commercial limitation was substitution. Physicians and payers could use immediate-release generic doxazosin for many patients, while BPH prescribers could select generic tamsulosin or other agents. A formulation patent could delay direct substitution for a specific extended-release product, but it did not preserve the broader doxazosin market.
Current investment value in Cardura XL formulation IP is low because:
- The product is old.
- The active ingredient is off patent.
- Multiple low-cost BPH alternatives exist.
- The market has limited willingness to pay for a branded delivery modification.
- Any formulation advantage has not created a durable premium franchise.
Which companies manufacture generic doxazosin?
Generic doxazosin has historically been supplied by a broad group of U.S. and international manufacturers, including large generic companies and contract manufacturers. The supplier list can change by dosage strength, product form, and regulatory status.
Relevant competitive categories include:
- Large U.S. generic companies.
- Indian pharmaceutical manufacturers.
- European and regional generic suppliers.
- Contract development and manufacturing organizations.
- Pharmacy wholesalers supplying private-label products.
The market is more fragmented than the original Cardura brand market, but generic competition can also contract when reimbursement becomes uneconomic. Supplier exits may create intermittent shortages, yet they do not restore Pfizer’s brand economics.
What patent litigation and Paragraph IV challenges affected Cardura?
Cardura’s major commercial event was generic entry after expiration of the core patent, not a continuing high-value patent litigation campaign. Paragraph IV litigation is most relevant when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or not infringed. For Cardura, any historical challenges were tied to the original product or later formulation listings and did not prevent long-term generic commoditization.
There is no current litigation profile comparable to newer drugs with active Orange Book patents, settlement agreements, pediatric extensions, or launch-at-risk disputes. The absence of active, economically important exclusivity means that generic competition is governed primarily by FDA approval, supplier economics, and payer substitution.
What is the FDA regulatory status of Cardura?
FDA-approved doxazosin products remain prescription drugs. Cardura and generic doxazosin are approved for hypertension, while doxazosin products are also used for BPH depending on the specific formulation and labeling.
Key regulatory considerations include:
- Dose titration because of first-dose syncope and orthostatic hypotension.
- Blood-pressure monitoring, particularly in older adults.
- Interaction risk with other blood-pressure-lowering agents.
- Caution with phosphodiesterase-5 inhibitors because of additive hypotension.
- Distinct labeling for immediate-release and extended-release products.
FDA approval does not create commercial exclusivity for an old generic drug. The regulatory value is maintenance of approved labeling and manufacturing compliance, not market protection.
How strong is the Cardura patent estate?
The Cardura patent estate is weak for commercial purposes.
| Patent-estate factor |
Assessment |
| Core active-ingredient protection |
Expired |
| Immediate-release tablet protection |
Expired or commercially irrelevant |
| Extended-release formulation protection |
Historical; no durable current moat |
| Method-of-use protection |
Limited practical value |
| Orange Book leverage |
Low |
| Biosimilar protection |
Not applicable |
| Manufacturing barriers |
Moderate for compliant suppliers, low for market entry |
| Litigation leverage |
Low |
| Brand pricing power |
Minimal |
Doxazosin is a small-molecule drug, so biosimilar rules do not apply. Competitors use the ANDA pathway for generic versions rather than the biosimilar pathway used for biologics. This distinction reduces development complexity and supports broad substitution.
What licensing deals or strategic transactions involve Cardura?
Cardura was developed and commercialized by Pfizer and did not become a major modern licensing platform. Publicly material licensing activity is limited compared with products whose rights were divided among regional pharmaceutical companies or specialty-drug developers.
The strategic value of doxazosin today is primarily as a generic product. Any supply, distribution, or private-label arrangements are unlikely to produce material royalty economics for the original brand owner. There is no evident current licensing structure that changes the competitive assessment.
What is the geographic coverage of Cardura exclusivity?
Cardura’s patent and regulatory history differs by jurisdiction, but the global pattern is consistent:
- United States: core exclusivity ended around 2000; generic competition is established.
- European markets: national and regional generic competition emerged after local patent and regulatory barriers expired.
- Japan and other regulated markets: approval, patent, and reimbursement timelines differed, but doxazosin became a mature generic medicine.
- Emerging markets: local manufacturers and branded generics may retain some name recognition, but pricing is generally constrained.
Geographic brand value may persist where physicians prescribe branded generics, but this does not equate to U.S.-style patent exclusivity. The commercial assessment must separate trademark persistence from enforceable pharmaceutical IP.
What is the outlook for Cardura revenue and market share?
Cardura’s original branded revenue is structurally low and unlikely to recover. The drug remains clinically useful, but utility does not translate into brand pricing power in a mature generic category.
The forward market outlook is:
- Stable or declining overall use in hypertension.
- Continued use in selected BPH patients.
- Persistent generic price pressure.
- Limited opportunity for premium reformulation.
- Possible supply volatility among individual manufacturers.
- No credible path to restoration of originator-level revenue.
The principal revenue exposure lies with generic manufacturers, wholesalers, and pharmacies rather than Pfizer. Even for generic suppliers, doxazosin is unlikely to be a major growth driver unless a shortage or competitor withdrawal temporarily improves pricing.
Key Takeaways
- Cardura is Pfizer’s branded doxazosin product for hypertension and BPH.
- Its core U.S. patent protection expired around 2000.
- The ALLHAT trial weakened doxazosin’s role in first-line hypertension treatment.
- Generic entry caused rapid price and market-share erosion.
- Cardura XL provided a formulation-based lifecycle extension but did not create durable premium economics.
- The current market is generic, mature, and price sensitive.
- No meaningful biosimilar risk exists because doxazosin is a small molecule.
- Current value depends on generic supply, reimbursement, and BPH prescribing rather than patent protection.
- Pfizer does not publicly report Cardura as a material standalone revenue product.
- The probability of a commercially significant Cardura brand revival is very low.
FAQs About Cardura Patents, Generics, and Market Value
Is Cardura still sold as a brand-name drug?
Cardura may remain available in some markets or through residual branded distribution, but U.S. prescribing is dominated by generic doxazosin. The brand has no meaningful exclusivity-based pricing power.
Can a generic manufacturer launch doxazosin without a patent settlement?
Yes. The core Cardura patent barrier expired, so generic manufacturers can rely on the ANDA pathway without needing a commercial settlement with Pfizer, subject to FDA approval and any product-specific patent issues.
Is Cardura XL interchangeable with generic immediate-release doxazosin?
Not automatically. Immediate-release and extended-release products have different release characteristics and labeling. Substitution depends on the product, dosage, state law, payer rules, and prescriber instructions.
Does doxazosin have a biosimilar competitor?
No. Doxazosin is a chemically synthesized small molecule. Competitors file abbreviated new drug applications, not biosimilar applications.
Could a doxazosin shortage increase Cardura’s value?
A temporary shortage could raise prices for selected suppliers or create localized demand for branded inventory. It would not restore long-term patent protection or recreate Cardura’s former revenue trajectory.
References
-
ALLHAT Collaborative Research Group. (2000). Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA, 283(15), 1967-1975. https://doi.org/10.1001/jama.283.15.1967
-
Pfizer Inc. (1999). 1998 annual report. Pfizer.
-
Pfizer Inc. (2000). 1999 annual report. Pfizer.
-
Pfizer Inc. (2001). 2000 annual report. Pfizer.
-
U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: Cardura. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (n.d.-c). Doxazosin mesylate prescribing information. FDA labeling database. https://labels.fda.gov/
